We have recently demonstrated that the exoNA approach is feasible for detection of the EGFR T790M mutation and yielded very high clinical performance (92% sensitivity and 89% specificity) for the detection of T790M in plasma of NSCLC patients [18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.